about
C3d of complement as a molecular adjuvant: bridging innate and acquired immunityA single centre experience of liver disease in adults with cystic fibrosis 1995-2006.Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver diseasePrednisolone or pentoxifylline for alcoholic hepatitis.The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Fatal reactivation of hepatitis B after chemotherapy for lymphoma.Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver diseaseSuccessful surgical management of ruptured umbilical hernias in cirrhotic patientsPersistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis CSirolimus-induced pneumonitis following liver transplantation.Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.Any value in a specialist review of liver biopsies? Conclusions of a 4-year review.In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA.Risk factors for recurrent primary sclerosing cholangitis after liver transplantation.Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey.The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS).Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity.Observations on the ex situ perfusion of livers for transplantation.A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis.26-hour Storage of a Declined Liver Before Successful Transplantation Using Ex Vivo Normothermic Perfusion.Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease.Vacuolation in hepatocyte nuclei is a marker of senescence.Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption.Non-invasive measurement of azygos venous blood flow using magnetic resonanceGuidelines for liver transplantation for patients with non-alcoholic steatohepatitisLow-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid non-invasive MRI techniqueAnalysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomesReply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode"ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be EstablishedIncidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patientsPrevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitisAccuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
P50
Q28272810-BE77EC17-A202-40B6-B797-91E4B4F74ABEQ33377573-869FAAEC-5804-4566-9CC4-841492D94EAFQ33728918-AAEF2394-7AFE-4E3E-95BE-F04502226B83Q34473050-BDA64EEA-5D46-4436-B2EC-E0B7261186BEQ34506101-8159FA37-6C44-46CA-AEF3-1098AD7554D1Q34785862-DD28BAE7-F7E4-4F03-897D-783308CAF2A4Q34791395-BFBE5D05-9D40-4333-B365-6D0C75837135Q35004683-B355B82D-8692-47CD-BEEB-6A7467824BB8Q35169414-0D858ABA-1509-47D7-A07B-333345D86E37Q35810396-0D2360E8-8CA6-4D9E-9D88-51CF8649C73CQ36835665-BA1F10FF-54F7-4A1F-B06F-21A84B6B1520Q38588334-3B633891-62DF-44B8-BD29-68FF0614898FQ38716556-7014EE79-37E2-4EE0-84E6-1FE7D8180565Q39043880-BE898370-D6E6-4CF4-80DA-2435C651D2E5Q40723811-139095D5-62E2-4855-8AE2-45B620A20E24Q42014196-B7746086-F430-4F34-8FD9-7DBC2186A6FFQ47234787-94CDE52D-9120-403A-AABA-680287E3F5E9Q47724879-429201B6-310F-40E4-9963-0C485A037F73Q47873703-B8AFDE0F-4F17-42E4-B477-C1BAEF70BB9DQ50116922-19930500-C81C-495A-8E9C-5B5BDAAC955AQ52843213-985DEB19-C7FF-4FEF-9F49-B2FBCEC60486Q53082282-5635BC23-6E64-4599-96D2-585E5B73A00AQ53134779-25A97ED5-4F9C-4550-B137-863F85B514D8Q53177735-61242756-A69F-4E6C-83FD-F4AFE3E4AFBDQ55315063-B179EA83-2F48-4965-A2AC-7A309E0E57B8Q57189764-32C21358-51D7-4956-A92F-38FF33A3D83BQ64449640-B932F9CD-D58E-4E65-BA36-F5CFEA8A8121Q80184924-7277B94D-B2EF-441B-8320-3388923B0C3BQ86419061-E58F59D9-1FB7-4394-84FC-4CC9D0BB1971Q88014270-28ACED31-5FA5-4472-81AD-5EC90AAC2269Q89055889-D8C0E695-CC8C-49B1-B135-FB65596C1EAEQ91057745-61758E64-CAA2-4A80-B64D-1C5AD95FFEE3Q91163899-F107BC84-4804-4235-A446-A1B9E012E8ECQ91251078-13570E87-153E-4013-AFFE-AC494DF18B2D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Allison
@ast
Michael Allison
@en
Michael Allison
@es
Michael Allison
@nl
Michael Allison
@sl
type
label
Michael Allison
@ast
Michael Allison
@en
Michael Allison
@es
Michael Allison
@nl
Michael Allison
@sl
prefLabel
Michael Allison
@ast
Michael Allison
@en
Michael Allison
@es
Michael Allison
@nl
Michael Allison
@sl
P106
P21
P31
P496
0000-0003-3677-3294
P569
2000-01-01T00:00:00Z